We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
+20.41%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$262M
AUM Growth
+$32.5M
Cap. Flow
+$705K
Cap. Flow %
0.27%
Top 10 Hldgs %
98.33%
Holding
14
New
–
Increased
2
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
SYRE icon
Spyre Therapeutics
SYRE
+$3.05M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$2.28M

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$4.63M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$130M 49.65%
3,989,412
– –
EIDX
2
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$53.6M 20.44%
1,123,630
– –
TECX
3
Tectonic Therapeutic
TECX
$529M
$17.6M 6.72%
84,148
– –
SYRE icon
4
Spyre Therapeutics
SYRE
$8.54B
$15.6M 5.97%
67,646
+16,000
+31% +$3.05M
SNDX icon
5
Syndax Pharmaceuticals
SNDX
$1.69B
$15.2M 5.8%
1,025,000
+150,000
+17% +$2.28M
BCEL
6
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$8.25M 3.15%
387,653
– –
OBSV
7
DELISTED
ObsEva SA Ordinary Shares
OBSV
$8.17M 3.12%
1,386,338
– –
MRKR icon
8
Marker Therapeutics
MRKR
$18.8M
$4.14M 1.58%
200,000
– –
VIRX
9
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.66M 1.02%
288,571
– –
ZSAN
10
DELISTED
Zosano Pharma Corporation
ZSAN
$2.33M 0.89%
77,664
– –
VRNA
11
DELISTED
Verona Pharma
VRNA
$2.07M 0.79%
443,596
– –
NBRV
12
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$1.29M 0.49%
7,641
– –
ACRS icon
13
Aclaris Therapeutics
ACRS
$726M
$1.03M 0.39%
634,455
– –
RCUS icon
14
Arcus Biosciences
RCUS
$3.55B
– –
-333,333
Closed -$4.63M

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Aisling Capital Management held 14 positions worth $262M, up 14% from $230M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Aisling Capital Management's Q2 2020 filing shows 2 increased and 1 closed positions. The largest sale was Arcus Biosciences, an estimated $4.63M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management added most to Spyre Therapeutics in Q2 2020, an estimated $3.05M increase.
  • Aisling Capital Management fully exited Arcus Biosciences in Q2 2020, selling an estimated $4.63M.
  • Aisling Capital Management's ten largest holdings make up 98% of its $262M portfolio in Q2 2020.
  • Aisling Capital Management opened 0 new positions and closed 1 in Q2 2020.
  • Aisling Capital Management's portfolio value rose 14% quarter-over-quarter to $262M.

Based on Aisling Capital Management's 13F filing for Q2 2020, filed 10 Aug 2020.